Know Cancer

forgot password

A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures

65 Years
Open (Enrolling)
Compression Fracture of Vertebral Body, Osteoporosis, Cancer.

Thank you

Trial Information

A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures

Inclusion Criteria:

1. Identified as an appropriate candidate for BKP and should have made the choice to
have the procedure.

2. Must be Medicare Eligible (At least 65 years of age or otherwise eligible).

3. Must have one to three target VCFs, located between T5 and L5, which are due to
underlying primary or secondary osteoporosis or cancer.

4. Cancer patients should not have had a change in chemotherapy regimen within the last
month, nor should they have a planned change within the next month from time of
enrollment, with the exception of changes in dose.

5. All VCFs to be treated must have clinical pain symptoms (pain on palpation/percussion
over the fractured vertebral body) that correlate with radiographic findings as

1. Height change: An acute (≤ four month) change in VB height or morphology from
a previous x-ray, CT or MRI, with height loss at the anterior, middle or
posterior portion of the VB consistent with a worsening of one or more grades by
the Genant criteria20, OR

2. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI, or
target VB is positive on radionuclide bone scan.

6. All VCFs to be treated must have an estimated fracture age of four months or less.

7. Treatment of all target VCFs must be technically feasible and clinically appropriate
for balloon kyphoplasty.

8. Pre-treatment back pain by numerical rating scale (NRS) score must be ≥ 7 (0-10
scale) and refractory to non-surgical management.

9. Pre-treatment Oswestry Disability Index must be ≥30 (0 - 100 scale).

10. Must have life expectancy of ≥ 12 months.

11. Must declare availability for all study visits.

12. Must be able to understand the risks and benefits of participating in the study and
be willing to provide written informed consent.

13. Must have the mental capacity necessary to comply with protocol requirements for the
12- month duration of study.

Exclusion Criteria:

1. Vertebral body morphology or fracture configuration contraindicative of balloon

2. VCFs due to high-energy trauma.

3. Asymptomatic VCFs or prophylactic treatment of non-fractured vertebral bodies.

4. VCFs accompanied at the same site by primary tumors of the bone (e.g., osteosarcoma),
solitary plasmacytoma or osteoblastic tumors.

5. Platelet count of <20,000/uL as measured at the time of hospital admission for the

6. Back pain due to causes other than acute fracture.

7. VCF with a clinically estimated (based on radiographic evidence as well as
patient history) age of fracture > four months.

8. VCF accompanied by objective evidence of secondary radiculopathy or neurologic

9. VCFs with the need for spinal surgery beyond balloon kyphoplasty.

10. Spinal cord compression or canal compromise requiring decompression.

11. Significant clinical comorbidity that may either contra-indicate
surgery or interfere with long-term data collection or follow-up.

12. Pre-existing conditions contrary to balloon kyphoplasty such as:

1. Allergy to any components (e.g., bone cement, contrast medium) of the balloon
kyphoplasty device/procedure.

2. Active or incompletely treated infection of the vertebral column or
active systemic infection, including unresolved urinary tract infection.

3. Irreversible coagulopathy or bleeding disorder.

13. Contraindications to both MRI and radionuclide bone scan.

14. Concurrent participation in another clinical study.

15. Pregnant or intending to become pregnant during the course of the study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change from baseline in back function by Oswestry Disability Index

Outcome Time Frame:

3 months

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

May 2013

Completion Date:

March 2016

Related Keywords:

  • Compression Fracture of Vertebral Body
  • Osteoporosis
  • Cancer.
  • vertebral body compression fracture
  • Fractures, Bone
  • Osteoporosis
  • Fractures, Compression



The Back CenterMelbourne, Florida  32901
Illinois Bone & JointMorton Grove, Illinois  60053
Clinical Investigations, LLCEdmond, Oklahoma  73013